chartexchange

FDC shares gain 5.96% as Q2 net profit surges 73% YoY to ₹49 Cr; board approves ₹120 Cr share buyback at ₹500 apiece

Trade Brains | Oct 28, 2026 2:59 AM EDT

The company is an Indian pharmaceutical company engaged in the development, manufacturing and marketing of pharmaceutical formulations and healthcare products. Its portfolio includes products across domestic and international markets, with brands such as Electral, Enerzal and Zifi. The company operates in domestic and international formulations, making product demand, distribution reach, export growth and operating margins important factors influencing its financial performance
The Nifty 50 is trading at 22,657.2, down by 0.41%, while the Sensex fell to 73,176.40, down by  0.57% on Wednesday. The shares of FDC are currently trading at Rs. 374.90, up by 5.96%. The company has a market capitalisation of Rs. 6,103.75 crore. The stock’s 52 week high is Rs. 473.60 and its 52 week low is Rs. 312.95 . In the past 6 mont,hs the stock has delivered a return of 2.59%.

Also Read: ACME Solar Holdings expands Rajasthan Bikaner BESS capacity to 195.35 MW as commercial operations approach

What’s the News?
FDC Limited announced its consolidated financial results for the quarter ended September 30, 2026, on October 27, 2026. Revenue from operations increased to Rs. 572.1 crore from Rs. 473 crore in Q2 FY26, while net profit rose to approximately Rs. 49 crore from Rs. 28.3 crore.
Alongside the results, the board approved a share buyback of up to 24 lakh equity shares at Rs. 500 per share, with a maximum aggregate value of Rs. 120 crore. The proposed buyback represents 1.47% of the company's paid-up equity capital and will be conducted through the tender offer route, subject to the applicable process and terms. <
Q2 Financial Performance
Looking at the quarterly results of FDC Limited, consolidated revenue from operations increased to Rs. 572.1 crore in Q2 FY27 from Rs. 473 crore in Q2 FY26, registering year-on-year growth of approximately 21%. However, revenue declined from Rs. 667.7 crore in Q1 FY27, reflecting a sequential moderation in sales.
EBITDA rose to Rs. 64.3 crore from Rs. 33.8 crore in the corresponding quarter last year, marking growth of approximately 90.2%. EBITDA margin improved to 11.2% from 7.1%, indicating a significant improvement in operating profitability.
Net profit increased to approximately Rs. 49 crore from Rs. 28.3 crore in Q2 FY26, representing growth of nearly 73%. However, net profit was lower than the Rs. 132.5 crore recorded in Q1 FY27. The sequential decline highlights the importance of examining quarterly variations alongside year-on-year growth.
Domestic Formulations Return to Growth
FDC's domestic formulations business recorded year-on-year growth of 22.6% in Q2 FY27. According to the company's results announcement, products including Electral and Enerzal contributed to performance, while Zifi returned to growth.
The recovery in domestic formulations is important because prescription medicines and consumer healthcare products form a key part of the company's business. Sustaining growth across established brands and improving product demand could support revenue in subsequent quarters.
The company also reported that it was among the fastest-growing companies in the top 25 of the Indian pharmaceutical market during the quarter, based on IQVIA September 2026 data cited in its press release.
International Formulations Support Growth
FDC's international formulations business also delivered positive momentum, growing 28.5% year-on-year in Q2 FY27. For the first half of FY27, international formulations growth stood at 47.6%, according to the company's announcement.
International markets provide an additional growth avenue beyond domestic demand. However, performance can be influenced by product registrations, market competition, currency movements and regulatory requirements across countries.
Continued growth in international formulations, alongside a recovery in domestic sales, could help the company diversify its revenue sources.
FDC Share Buyback: Key Details for Investors&nbsp;
FDC Limited's board has approved a share buyback worth up to Rs. 120 crore, under which the company will repurchase up to 24 lakh fully paid equity shares at Rs. 500 per share. The buyback represents approximately 1.47% of the company's paid-up equity capital and will be carried out through the tender offer route.
The company has fixed November 13, 2026, as the record date to determine eligible shareholders. The board has also noted the intention of the promoters and promoter group to participate in the buyback.
What the Buyback Means for Investors
A share buyback allows a company to return a portion of its capital to eligible shareholders. Under a tender offer, shareholders can offer shares for repurchase at the announced price, subject to the applicable acceptance ratio.
FDC's proposed price of Rs. 500 per share is the announced buyback price, not a guarantee that every share tendered by an investor will be accepted. Investors should review the company's public announcement for the final schedule, eligibility requirements and acceptance details.
A buyback can improve capital allocation when a company has surplus funds, but investors should also consider the company's future investment requirements, cash position and business outlook

Read original article